
    
      The protocol was primarily amended for the following reason:

      Merck's tetravalent HPV vaccine, GardasilÂ®, has been licensed and is now becoming
      commercially available in an increasing number of countries. Therefore, the study procedures
      were revised to include questions at every visit to determine if subjects have received an
      HPV vaccine outside of the study.
    
  